Forest Lin

Forest Lin

Auto-generated profile, based on publicly available information

Forest Lin

University of Southern California

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2026 in Ophthalmology Retina
Verified
Journal Article
Closed access
AHAlexander Hong
Alexander Hong
FLForest Lin
Forest Lin
JKJeremy D. Keenan
Jeremy D. Keenan
JSJay Stewart
Jay Stewart

6 December 2025 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
AHAlexander Hong
Alexander Hong
FLForest Lin
Forest Lin
Sally BaxterSally Baxter
Sally Baxter
RWRobert N Weinreb
Robert N Weinreb

19 June 2025 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
ILIvan Yun-Kuen Luu
Ivan Yun-Kuen Luu
AHAlexander Hong
Alexander Hong
FLForest Lin
Forest Lin
LSLaura Shin
Laura Shin
CSChia-Ding Shih
Chia-Ding Shih
TTTze-Woei Tan
Tze-Woei Tan

19 April 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
AHAlexander Hong
Alexander Hong
ILIvan Yun-Kuen Luu
Ivan Yun-Kuen Luu
FLForest Lin
Forest Lin
AVArjun P Vij
Arjun P Vij
KLKatherine A Lewis
Katherine A Lewis
JKJeffrey D Klausner
Jeffrey D Klausner
Introduction: Herpes simplex virus 1 (HSV-1) infects approximately two-thirds of the global population under the age of 50 years. Although widely prevalent, the possible implications of HSV-1 in neurodegenerative diseases, especially dementia and Alzheimer’s disease, remain poorly understood. This review seeks to elucidate this association and explore the potential benefits of preventing or treating herpesvirus infections on dementia risk. The goal is to enhance our understanding of HSV-1’s potential role in dementia, which could inform the development of future therapeutic interventions for these conditions. Methods and analysis: PubMed, Embase (Elsevier/Ovid), Web of Science, Scopus, Global Health, PsycInfo, Cochrane Library and Clinicaltrials.gov will be searched from the inception of each respective database. Studies that have HSV-1 as an exposure and dementia, or its subtypes, as a primary outcome will be included. Two researchers will independently screen titles, abstracts and full texts, with discrepancies resolved by a third researcher. Systematic data extraction from eligible studies will be performed using a standardised template. Risk of bias of individual studies will be assessed with the Cochrane Collaboration approach. We will assess the overall quality of cumulative evidence using the Grading of Recommendations, Assessment, Development and Evaluations criteria. Statistical analysis will employ a random effects model, and heterogeneity will be determined with Cochrane’s Q test and assessed using I 2 . Studies will be grouped by population subgroups and dementia subtypes when possible to explore nuances in results. We will consider performing meta-regression if heterogeneity remains after subgroup analyses. All statistical analyses will be conducted using Stata V.18 software (College Station, Texas, USA). Ethics and dissemination: No ethical approval is required since data will be collected from existing studies. The review will be disseminated through peer-reviewed publication and at national and international conferences. PROSPERO registration number: CRD42024516789.

5 September 2025 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
AHAlexander Hong
Alexander Hong
ILIvan Yun-Kuen Luu
Ivan Yun-Kuen Luu
FLForest Lin
Forest Lin
TTTze-Woei Tan
Tze-Woei Tan
BTBrian C. Toy
Brian C. Toy

12 February 2026 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
JCJason Shin Chwa
Jason Shin Chwa
AHAlexander Hong
Alexander Hong
FLForest Lin
Forest Lin
WZWilliam Zeng
William Zeng
ZLZhiwen Joseph Lo
Zhiwen Joseph Lo
TTTze-Woei Tan
Tze-Woei Tan